Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 30;35(1):27.
doi: 10.1186/s43046-023-00186-z.

Mechanisms of HIF-driven immunosuppression in tumour microenvironment

Shinjini Bandopadhyay  1 , Somi Patranabis  2
Affiliations
Review

Mechanisms of HIF-driven immunosuppression in tumour microenvironment

Shinjini Bandopadhyay et al. J Egypt Natl Canc Inst. .

Abstract

Hypoxia arises due to insufficient oxygen delivery to rapidly proliferating tumour cells that outpace the available blood supply. It is a characteristic feature of most solid tumour microenvironments and plays a critical role in regulating anti-tumour immunity, enhancing tumoral heterogeneity, and promoting therapeutic resistance and poor clinical outcomes. Hypoxia-inducible factors (HIFs) are the major hypoxia-responsive transcription factors that are activated under low oxygenation conditions and have been identified to drive multifunctional roles in tumour immune evasion. The HIF signalling network serves as an attractive target for targeted therapeutic approaches. This review aims to provide a comprehensive overview of the most crucial mechanisms by which HIF controls the expression of immunosuppressive molecules and immune checkpoints, disrupts cancer immunogenicity, and induces immunotherapeutic resistance.

Keywords: HIF; Hypoxia; Immunotherapy; Tumour immunogenicity; Tumour microenvironment.

PubMed Disclaimer

References

    1. Bremnes Roy M, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6(1):209–17. https://doi.org/10.1097/JTO.0b013e3181f8a1bd . - DOI - PubMed
    1. Ramamonjisoa N, Ackerstaff E. Characterization of the tumor microenvironment and tumor-stroma interaction by non-invasive preclinical imaging. Front Oncol. 2017;7(3):31. https://doi.org/10.3389/fonc.2017.00003 . - DOI
    1. Fu T, et al. “Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98. https://doi.org/10.1186/s13045-021-01103-4 . - DOI - PubMed - PMC
    1. Chew V, et al. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406. https://doi.org/10.1155/2012/608406 . - DOI - PubMed - PMC
    1. Lei X, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer let. 2020;470:126–33. https://doi.org/10.1016/j.canlet.2019.11.009 . - DOI

Substances